US20210267912A1 - Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes - Google Patents
Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes Download PDFInfo
- Publication number
- US20210267912A1 US20210267912A1 US17/252,676 US201817252676A US2021267912A1 US 20210267912 A1 US20210267912 A1 US 20210267912A1 US 201817252676 A US201817252676 A US 201817252676A US 2021267912 A1 US2021267912 A1 US 2021267912A1
- Authority
- US
- United States
- Prior art keywords
- msm
- diabetes
- containing composition
- vitamin
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 37
- 208000008589 Obesity Diseases 0.000 title claims abstract description 34
- 235000020824 obesity Nutrition 0.000 title claims abstract description 34
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 23
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 23
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 23
- 230000003405 preventing effect Effects 0.000 title claims abstract description 21
- 229940016409 methylsulfonylmethane Drugs 0.000 title claims abstract description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 20
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019152 folic acid Nutrition 0.000 claims abstract description 13
- 239000011724 folic acid Substances 0.000 claims abstract description 13
- 229960000304 folic acid Drugs 0.000 claims abstract description 13
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 11
- 239000011777 magnesium Substances 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- 241000209094 Oryza Species 0.000 claims 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 210000001789 adipocyte Anatomy 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000004069 differentiation Effects 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 102000013275 Somatomedins Human genes 0.000 abstract description 2
- 235000009200 high fat diet Nutrition 0.000 description 43
- 239000003814 drug Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 229940079593 drug Drugs 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
- 102000014429 Insulin-like growth factor Human genes 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 238000013116 obese mouse model Methods 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 239000003925 fat Substances 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 235000021590 normal diet Nutrition 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000028327 secretion Effects 0.000 description 13
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 239000011593 sulfur Substances 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000018997 Growth Hormone Human genes 0.000 description 7
- 108010051696 Growth Hormone Proteins 0.000 description 7
- 230000035508 accumulation Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 239000000122 growth hormone Substances 0.000 description 7
- 230000003914 insulin secretion Effects 0.000 description 7
- 230000004130 lipolysis Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000006694 eating habits Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019159 vitamin B9 Nutrition 0.000 description 2
- 239000011727 vitamin B9 Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001236253 Pinus aristata Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 150000001787 chalcogens Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Abstract
The present invention relates to a methyl-sulfonyl methane containing composition for preventing or alleviating obesity, fatty liver and diabetes. An MSM (methyl sulfonyl methane: dimethyl sulfone)-containing composition according to the present invention, which contains 75 to 85 wt. % of MSM, 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galacto-oligosaccharide, 10 to 18 wt. % of rice-fermented magnesium, and 0.5 to 3 wt. % of vitamin C, not only can prevent and treat obesity by reducing the size of fat cells and inhibiting differentiation of mature fat cells, but also lowers triglyceride and the total cholesterol concentration in the liver, thus having a fatty liver preventing effect, and also reduces the concentration of insulin-like growth factor, thus also being effective for diabetes. Therefore, the MSM-containing composition is expected to be useful as a pharmaceutical composition and food composition for preventing and alleviating obesity, fatty liver and diabetes.
Description
- The present invention relates to a composition for preventing or alleviating obesity, fatty liver and diabetes, which contains methylsulfonylmethane.
- As visceral fat-type obesity increases due to changes in dietary habits, development of metabolic syndrome involving fatty liver, abnormal lipid metabolism, diabetes, insulin resistance, high blood pressure, etc. is becoming an ever greater societal problem. These diseases increase the risk of mutual development thereof and are common diseases associated with multiple metabolic changes such as aging, stress, and immune dysfunction.
- The main causes of fatty liver are alcoholism, obesity and diabetes mellitus due to overeating, and fatty liver may also occur in other cases including use of medicine with strong toxicity, misuse of antibiotics during pregnancy, abuse of aspirin for alleviating fever of young children who have infectious diseases, etc. Such fatty liver may be easily recovered by regeneration of hepatocytes if physical conditions such as immune status are favorable. If not, fat mass in hepatocytes grows to push important components in the cells including nuclei to one side, which in turn deteriorates functions of hepatocytes. Further, due to accumulated fat in the cells, expanded hepatocytes may press blood vessels and lymphatic glands therebetween, hence causing impaired circulation of blood and lymphatic fluid in the liver. Further, hepatocytes cannot properly receive oxygen and nutrients, thus deteriorating liver function, which in turn causes progression to hepatocirrhosis.
- Hyperlipidemia is a condition in which too many fatty components are present in the blood and accumulated on a blood vessel wall, causing inflammation and therefore cardiovascular disease. Hyperlipidemia is classified into hypertriglyceridemia, hyperemia and hypercholesterolemia and, recently, may also include so-called dyslipidemia that includes increase in triglycerides, total cholesterol and LDL-cholesterol, or reduced HDL-cholesterol in blood. This disease has no specific symptom but causes arteriosclerosis, which may lead to coronary heart disease, cerebrovascular disease, and peripheral vascular occlusion. In addition, excessive fat accumulation may also affect the liver and therefore is closely related to fatty liver development.
- Obesity is not just high weight but a state of excessive accumulation of body fat. This means that, even if a person looks normal but has a high body fat percentage, this state may refer to obesity. In general, obesity is determined by body mass index (BMI). More particularly, a BMI of 23 to 24.9 is classified as overweight, while a BMI of 25 to 29.9 is classified as mild obesity. Further, if BMI is 30 to 34.9, this is determined as moderate obesity, while being extremely obese when BMI is 35 or more. Obesity is caused by a combination of multiple factors rather than a single cause, for example, bad dietary habits including westernized dietary habits, decreased performance, emotional factors, genetic factors, etc. Such developed obesity may therefore increase the risk of developing chronic diseases including hyperlipidemia, diabetes, high blood pressure, etc.
- Obesity refers to a state in which body fat is excessively accumulated and corresponds to a body fat percentage of 25% or more in men and 30% or more in women, or a body mass index (BMI) of 30 kg/m2 or more. As a cause of obesity, environmental factors such as excessive caloric intake and lack of exercise due to lifestyle changes have emerged. Meanwhile, diabetes associated with obesity is classified into insulin dependent diabetes mellitus (type I diabetes mellitus), insulin independent diabetes mellitus (type II diabetes mellitus), and malnutrition diabetes mellitus (MRDM). Herein, Type II diabetes accounts for more than 90% of Korean diabetes patients, is a metabolic disease characterized by hyperglycemia and is reported to be caused by decreased insulin secretion of pancreatic beta cells or increased insulin resistance in peripheral tissues due to genetic, metabolic and environmental factors. Diabetes is closely related to obesity and prevalence mechanisms. In this regard, when body fat increases with obesity, insulin sensitivity tends to decrease. Further, in case of patients with type II diabetes, obesity is closely correlated with insulin resistance and, therefore, it is known that the greater the obesity, the greater the insulin resistance.
- Current medicaments to treat obesity may be generally divided into drugs acting on the central nervous system to affect appetite and drugs acting on the gastrointestinal tract to inhibit absorption. Drugs acting on the central nervous system may include, for example: drugs to inhibit the serotonin (5HT) nervous system according to respective mechanisms such as fenfluramine and dexfenfluramine; drugs acting though the noradrenaline nervous system such as ephedrine and caffeine; and drugs simultaneously acting on both serotonin and noradrenaline nervous systems to inhibit obesity such as sibutramine, which are recently and commercially available. Further, drugs acting on the gastrointestinal tract may include orlistat recently approved as an anti-obesity agent, which is a representative medicine to inhibit lipase produced in the pancreas so as to reduce fat absorption. However, among conventionally used anti-obesity agents, fenfluramine has recently been prohibited due to side effects such as primary pulmonary hypertension and heart valve lesions. Further, sibutramine has side effects of increasing blood pressure, and orlistat is known to have side effects such as digestive problems. In addition, other chemical synthetic drugs also caused problems such as blood pressure reduction or lactic acidosis and, therefore, could not be used in patients with specific diseases such as heart failure and kidney disease.
- In other words, a novel method for prevention or treatment of obesity and diabetes closely associated with the same while reducing side effects of existing medicaments is needed. In recent years, research to find a solution from natural materials is being actively performed. That is, there is a requirement for a treatment method with anti-obesity and anti-diabetic functions through effects of body weight gain inhibition, reduced fat accumulation, fat cell size reduction, fatty liver improvement, blood lipid alleviation, blood sugar reduction and reduced insulin resistance, using natural materials. The present invention has been proposed in view of such points.
- Diabetes is a disease in which glucose present in the blood is excreted through urine, and is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia due to a lack of insulin secretion or a lack of insulin action. Diabetes may be roughly divided into type I diabetes (insulin-dependent) and type II diabetes (insulin-independent). The etiology of type II diabetes is known to be a combination of insulin secretion disorder and insulin resistance.
- More than 95% of diabetes mellitus is type II diabetes, which is rapidly increasing due to changes in the living environment including westernized dietary habits, increased stress and aging population, according to rapid economic development.
- Diabetes, known as a representative adult metabolic disease, is also progressing to digestive diabetes, which in turn causes serious concerns. About 5% of the world's population suffers from diabetes and the prevalence of diabetes mellitus in Korea is between 5 and 10%. As of 2014, 20.7 deaths per 100,000 population among the major causes of death were cancer, heart disease, cerebrovascular disease, ischemic heart disease and diabetes in sequential order, resulting in enormous human and economic losses (National Statistical Office, 2015).
- Insulin secretion disorder refers to a situation in which an appropriate amount of insulin is not secreted from beta cells of the pancreas depending on the blood glucose level. This is due to the quantitative decrease in insulin secreting beta cells or impaired functional distribution of beta cells.
- Insulin resistance refers to a situation in which secreted insulin has reached the target organ via the bloodstream, however, insulin action and sensitivity are reduced in the target cell. In general, insulin resistance is thought to be a signaling disorder in which intracellular signals generated after binding insulin to a cell membrane insulin receptor has reduced signal intensity due to some causes. Insulin secretion disorder and insulin resistance may act in combination with each other to make diabetes worse. In other words, if insulin resistance is present, a larger amount of insulin must be secreted to overcome the same. On the contrary, hyperglycemia caused by insufficient insulin secretion may further worsen insulin resistance.
- Current treatment methods for insulin-independent diabetes include, for example, meal therapy, exercise therapy and pharmacotherapy. Pharmacotherapy is applied to clinical treatment using various drugs, for example: sulfonylurea-based drugs to increase insulin secretion; peroxisome proliferator activated receptor gamma (PPAR-γ)-enhancing drugs to improve insulin activity; α-glucosidase inhibitor-based drugs (e.g. acarbose) to inhibit digestion and absorption of carbohydrates and to prevent elevation of postprandial blood sugar level; biguanide-based drugs (e.g. metformin) to promote glucose uptake into cells; insulin with different durations, etc.
- However, such therapeutic agents have problems of low efficacy or different side effects such as liver dysfunction, hypoglycemia, lactic acidosis and the like. Therefore, it is necessary to develop a safe diabetes therapeutic agent available for long-term use while having reduced side effects. In response to such requirements, studies are being actively conducted to search for diabetes treatment drugs from natural materials. In 1990, the World Health Organization (WHO) strongly recommended the use of natural products that are effective in diabetes and have reduced side effects (Grover J K et al., J. Ethnopharmacol., 73, pp 461-470, 2000).
- However, although strict blood glucose control is known to prevent or delay the development of diabetic complications, drugs effective in treating type II diabetes are insufficient for strict blood glucose control or for preventing complications of diabetes. Therefore, a novel therapeutic agent is required.
- Meanwhile, sulfur is an oxygen group element, that is, a chalcogen (element symbol: S, atomic number: 16, atomic weight: 32.06, melting point: 112.8° C. (α sulfur), boiling point: 444.7° C., specific gravity: 2.07 (α-sulfur)), which is produced in a free state as natural sulfur on the earth, but is also broadly present as a compound. Sulfur is the fourth most abundant mineral in the body after calcium, phosphorus and potassium, is found in every cell in the body, is a component of major amino acids such as cystine, cysteine and methionine, and is essential for the life of cells. Further, sulfur is a component of vitamins such as thiamin and biotin and is also present in saliva, bile and hormone insulin.
- Sulfur accounts for 0.15% of the human body weight and also for 10% of the mineral content in the body. As such, sulfur is one of the most important substances in metabolic activities such as breathing and assimilation of living things. Since ancient times, sulfur is known to be effective in conserving human vigor. Regularly prepared sulfur is the best remedy to treat a lack of vigor and has been used as a medicine for gynecological pediatric diseases, including various ulcers, inflammations and colds. According to Huh Jun's DonguiBogam (“The Principles and Practice of Eastern Medicine”), “Sulfur has a lot of heat and strong toxicity, but may remove chill in the body to help a lack of vigor, pathologic accumulation (a disease that mass is generated in the stomach due to long term indigestion in Chinese medicine) and poor energy (bad energy that brings illness to the body, such as exterior fever and chill, in Chinese medicine). Further, sulfur has detoxification effects.
- Methylsulfonylmethane (MSM: dimethyl sulfone) is a dietary form of sulfur that is nontoxic and odorless, and is found in the ocean, the atmosphere, plant tissues, animal tissues and human bodies. This compound is extracted from California Bristlecone pines and is a natural product made from lignin which is a natural organic sulfur compound as a biomaterial. As a result of animal toxicity test, the half lethal dose of MSM is more than 20 g per 1 kg of body weight, which is equal to the half lethal dose of water. Therefore, MSM has safety substantially similar to water and, even if it is taken for a long term, is safe. With regard to efficacy of MSM, it is known that MSM is effective in alleviating pain, skin redness and itching of knee osteoarthritis. Further, according to literature [MSM Miracle. The Official website of the MSM Medical Information Foundation. 2005-2006], it is reported that MSM is effective in treating inflammation caused by autoimmune diseases.
- Vitamin B6 hydrochloride is a water-soluble vitamin not stored by the body and is excreted in urine. Vitamin B6 exists in three forms: pyridoxal, pyridoxine and pyridoxamine. Vitamin B6 is involved in energy metabolism, especially protein metabolism, and is significant for circulatory, nervous and immune systems. Folic acid is a type of vitamin, also called vitamin B9 or vitamin M. Because of importance for development of nerves and blood vessels in the fetus, this is recommended for pregnant women before and during pregnancy and is abundant in fruits.
- Therefore, during continuous research to develop functional foods including MSM as an active ingredient, the present inventors have found that a composition containing vitamin B6 hydrochloride and folic acid as well as MSM may reduce a size of adipocytes and inhibit differentiation of mature adipocytes so as to prevent and treat obesity, may decrease triglyceride and total cholesterol levels in the liver to exhibit fatty liver preventing effects, in addition, may reduce a concentration of insulin-like growth factor so as to exhibit effects on diabetes, thereby completing the present invention.
- A technical problem to be solved in the present invention, that is, an object of the present invention, is to provide a pharmaceutical and food composition for preventing or alleviating obesity.
- Another object of the present invention is to provide a pharmaceutical and food composition for preventing or improving fatty liver.
- A further object of the present invention is to provide a pharmaceutical and food composition for preventing or alleviating diabetes.
- In order to solve the above technical problems, that is, in order to accomplish the above objects, the present invention may provide a pharmaceutical and food composition for preventing or alleviating obesity, which includes 75 to 85% by weight (“wt. %”) of methylsulfonylmethane (MSM: dimethyl sulfone), 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galactooligosaccharide, 10 to 18 wt. % of rice fermented magnesium, and 0.5 to 3 wt. % of vitamin C.
- In order to accomplish the above objects, the present invention may provide a pharmaceutical and food composition for preventing or improving fatty liver, which includes 75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone), 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galactooligosaccharide, 10 to 18 wt. % of rice fermented magnesium and 0.5 to 3 wt. % of vitamin C.
- In order to accomplish the above objects, the present invention may provide a pharmaceutical and food composition for preventing or alleviating diabetes, which includes 75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone), 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galactooligosaccharide, 10 to 18 wt. % of rice fermented magnesium and 0.5 to 3 wt. % of vitamin C.
- The composition of the present invention may include to 85 wt. % of MSM based on a total weight of the composition. At this time, when a content of MSM is less than 75 wt. %, effects of preventing obesity, fatty liver and diabetes, which are objective effects of the present invention, cannot be obtained. On the other hand, when a content of MSM is more than 85 wt. %, the above effects are not proportional to an increase in content, that is, the inventive composition may be inefficient. In addition, there is a problem of not ensuring formulation stability.
- The pharmaceutical composition may have any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, lyophilizers and suppositories, which may be a variety of oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used to prepare the formulation. Solid form preparations for oral administration may include tablets, pills, powders, granules, capsules and the like, and such solid form preparations may be prepared by mixing at least one compound with at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. Further, in addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration may include suspensions, liquid solutions, emulsions, syrups, etc. Other than simple and commonly used diluents such as water and liquid paraffin, diverse excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may also be included. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. may be used. As a basic material of the suppository, Witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, etc. may be used.
- The composition of the present invention may be administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and an effective dose level may be determined in consideration of individual type and severity, age, gender, type of disease, activity of drug, sensitivity to drug, time of administration, route of administration, release rate, duration of treatment, factors including concurrently used drugs, other factors well known in the field of medicine. The composition of the present invention may be administered as a therapeutic agent alone or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. Further, single or multiple administrations may be possible. Taking all of the above factors into consideration, administering an amount that can afford maximum effects in a minimum amount without side effects is important, and such amount may be easily determined by those skilled in the art. Preferred dosage of the composition of the present invention may depend on condition and body weight of a patient, extent of disease, drug type, administration route and duration of administration. In fact, a suitable total daily dose may be determined by a practitioner with suitable medical experience. Generally, an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, and more preferably 0.1 to 100 mg/kg may be administered once or several times per day. The composition is not particularly limited as long as this is applied to a subject for alcohol decomposition purposes, and is applicable to any subject. For example, the composition may be applied to any individual such as non-human animals including, for example, monkeys, dogs, cats, rabbits, marmots, rats, mice, cattle, sheep, pigs, goats, etc., as well as humans, birds and fishes. A mode of administration may include any conventional method used in the art without limitation. For example, the composition may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine or cerebrovascular injection.
- As one specific embodiment, the present invention provides a functional food composition for prevention of obesity, fatty liver and diabetes, which contains MSM as an active ingredient.
- When using the composition of the present invention in food, the composition may be added as is, or used with other health foods, health functional foods or health functional food ingredients, and may be suitably used in accordance with any conventional method. A mixing amount of the active ingredient may be appropriately determined depending on intended use. In general, the composition of the present invention may be added in an amount of preferably 15 parts by weight (“wt. parts”) or less, more preferably 10 wt. parts or less with respect to the raw material in the manufacture of food or beverage. However, in the case of long-term intake for purposes of health control and hygiene, the amount may be below the above range. Indeed, since no problem is present in terms of stability, the active ingredient may also be used in an amount greater than the above range.
- Types of foods possibly including the composition of the present invention are not particularly limited, and specific examples may include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums and dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., may include all foods within common sense, and may further include foods used as feed for animals. In addition, when the food composition of the present invention is used in the form of a beverage, additional ingredients such as various sweetening agents, flavoring agents or natural carbohydrates, etc. may be contained as in general beverages. Natural carbohydrate may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. A fraction of the natural carbohydrate is not limited thereto but is preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g with respect to 100 ml of the composition of the present invention. The sweetener may be a natural sweetener such as thaumatin, stevia extract, etc., and a synthetic sweetener such as saccharin, aspartame, etc. In addition to the above, the food composition of the present invention may include various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. Others such as pulp for production of natural fruit juices, fruit juice drinks and vegetable drinks may be included.
- As used herein, the term “administration” means introducing the pharmaceutical composition of the present invention to an individual in any suitable manner, and the route of administration may include various oral or parenteral routes as long as the composition can reach the target tissue via the route. The treatment method of the present invention may include administering a pharmaceutical composition comprising MSM in a pharmaceutically effective amount. A suitable total daily dose may be determined by a practitioner within a range according to the correct medical judgment, and is generally determined in an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, more preferably 0.1 to 100 mg/kg, which may be administered once to several times daily.
- However, for the purposes of the present invention, a therapeutically effective amount for a particular patient is preferably and differently applied on the basis of various factors, for example: type and extent of reaction to be achieved; optionally whether or not other agents are used; specific compositions; age, body weight, general state, gender and diet of a patient; administration time, administration route and secretion rate of composition; duration of treatment; and other drugs used along with or concurrent with the specific compositions, as well as other similar factors well known in the field of medicine.
- The MSM-containing composition according to the present invention can prevent and treat obesity by reducing a size of adipocytes and inhibiting differentiation of mature adipocytes, can reduce triglycerides and total cholesterol levels in the liver to exhibit fatty liver prevention effects, and is also effective on diabetes by decreasing a concentration of insulin-like growth factors. Therefore, it is expected that the inventive composition may be usefully used as a pharmaceutical and food composition for preventing and alleviating obesity, fatty liver and diabetes.
- The following drawings attached to this specification are provided to illustrate exemplary embodiments of the present invention, and will serve to further illustrate the technical spirit of the present invention together with the above-described contents of the present invention. Therefore, it should not be construed that the present invention is limited to the matters described in the drawings.
-
FIG. 1 is graphs illustrating effects of the MSM-containing composition according to the present invention on change of adipose tissues (epididymal cells) as a result of experiments for different groups, which are divided into: normal diet group (NCD); high fat diet group (HFD); high fat diet and MSM-containing composition intake group (HFD+MSM (0.0088%)); and high fat diet and MSM-containing composition intake group (HFD+MSM (0.017%)). -
FIG. 2 is graphs illustrating effects of the MSM-containing composition according to the present invention on change of liver tissues as a result of experiments for different groups, which are divided into: normal diet group (NCD); high fat diet group (HFD); high fat diet and MSM-containing composition intake group (HFD+MSM (0.0088%)); and high fat diet and MSM-containing composition intake group (HFD+MSM (0.017%)). -
FIG. 3 is micrographs showing liver tissue morphology in a high fat diet obese mouse model by the MSM-containing composition. -
FIG. 4 is micrographs showing liver tissue morphology in a high fat diet obese mouse model by the MSM-containing composition. -
FIG. 5 is micrographs showing 3T3-L1 cell differentiation inhibitory effects in a high fat diet obese mouse model by the MSM-containing composition. -
FIG. 6 is graphs illustrating measured results of change in liver triglyceride content in obese mice by the MSM-containing composition. -
FIG. 7 is graphs illustrating measured results of change in total liver cholesterol content in obese mice by the MSM-containing composition. -
FIG. 8 illustrates a result of in vitro lipolysis experiment using milk coffee with the MSM-containing composition. -
FIG. 9 illustrates a result of in vitro lipolysis experiment using Korean chicken soup (“Samgyetang”) with the MSM-containing composition. -
FIG. 10 is graphs showing IGF-1 secretion ability of the MSM-containing composition. - Hereinafter, preferred examples and the like are provided to facilitate understanding of the present invention. However, the following examples are provided only to more easily illustrate the present invention, and the contents of the present invention are not limited by the same.
- A composition containing methylsulfonylmethane (“MSM-containing composition”) having a constitutional composition as shown in Table 1 below was prepared.
-
TABLE 1 No. Component Content (%) 1 MSM 80.000 2 Vit. B6 1.100 3 Folic Acid 0.050 4 Galactooligosaccharide 4.000 5 Rice fermented magnesium 13.399 6 Vit. C 1.450 7 Vit. B12 mixed powder 0.001 Total 100 - As experimental animals, C57BL/6 series 8-week-old male mice were adapted with solid feed for 1 week, and were divided into 3 groups with an average body weight of 25 g according to randomized block design and bred for 8 weeks.
- The experimental groups were divided into: a normal diet group (NCD); a high fat diet group (HFD); a group having a high fat diet and the MSM-containing composition obtained in Example 1 (HFD+MSM (0.0088%)); a group having a high fat diet and the MSM-containing composition obtained in Example 1 (HFD+MSM (0.017%)), followed by implementing experiments. The normal diet group was fed a general diet wherein fat was 10% of total calories, while the high fat diet group was fed a diet wherein fat was 60% of total calories. Further, with regard to the groups having ingested the high fat diets together with the MSM-containing compositions, the diets fed to these groups were prepared by adding 0.0088% and 0.017% MSM-containing compositions, respectively, to the high fat diets. During the breeding period, water and feed were freely afforded. A temperature in the breeding space was maintained at 22±1° C. while illumination was controlled on 12-hour cycle (08:00 to 20:00). All animal experiments were performed while complying with Animal Experimentation Ethic Code under approval of the Science and Technology Institutional Animal Care and Use Committee.
- The results obtained in the experiments were expressed as the average±standard error for each experimental group, and statistical analysis of the mean difference between the two groups was analyzed by Student's t test, followed by verifying significance of the result at P<0.05 level.
- Dietary intake and body weight of the test animals were measured once a week. The body weight gain rate of each experimental group was measured at a predetermined time and a predetermined interval of 1 week during the experimental period, and the food efficiency ratio (FER) was calculated by dividing total body weight gain by dietary intake during the experimental period, which was defined as a duration from the feeding date of the experiment diet to the sacrifice date.
- Effects of the MSM-containing composition according to the present invention on dietary intake and body weight are shown in Table 2 for individual groups.
-
TABLE 2 Food Total body Total efficiency Test weight gain dietary ratio group (g) intake (g) (FER) (%) p-value NCD 5.3 42.13 12.5 ± 1.7 — HFD 21.3 31.30 68.1 ± 3.9 0.000 HFD + 11.7 31.32 37.9 ± 7.8 0.031 MSM (0.008%) HFD + 11.6 31.00 38.9 ± 4.0 0.003 MSM (0.018%) - As shown in Table 2, FER of the high fat diet group was about 5.4 times higher than the normal diet group, but it was found that FER of the high fat diet+MSM-containing composition intake group was decreased by about 1.8 times, as compared to the normal diet group. On the other hand, as compared to the normal diet group, the body weight was rapidly increased in the high fat diet group while the body weight gain in the high fat diet+MSM-containing composition intake group was significantly reduced. Therefore, it could be confirmed that intake of the MSM-containing composition significantly inhibits body weight gain caused by the high fat diet.
- Breeding, diet and statistical treatment of the experimental animals were performed in the same manner as in Experimental Example 1. In order to confirm fat accumulation inhibitory effects of the MSM-containing composition according to the present invention, the fat and liver tissues of the test animals were separated and weighed.
-
FIG. 1 is graphs illustrating effects of the MSM-containing composition according to the present invention on change of adipose tissues (epididymal cells) as a result of experiments for different groups, which are divided into: normal diet group (NCD); high fat diet group (HFD); high fat diet and MSM-containing composition intake group (HFD+MSM (0.0088%)); and high fat diet and MSM-containing composition intake group (HFD+MSM (0.017%)). -
FIG. 2 is graphs illustrating effects of the MSM-containing composition according to the present invention on change of liver tissues as a result of experiments for different groups, which are divided into: normal diet group (NCD); high fat diet group (HFD); high fat diet and MSM-containing composition intake group (HFD+MSM (0.0088%)); and high fat diet and MSM-containing composition intake group (HFD+MSM (0.017%)). - As shown in
FIGS. 1 and 2 , the weight of adipose tissues in a higher level was measured in the high-fat diet group compared to the normal diet group. On the other hand, it could be seen that that adipose tissues were reduced in the group having the high-fat diet together with the MSM-containing composition. - Breeding, diet and statistical treatment of experimental animals were performed in the same manner as in Experimental Example 1. For morphological observation of the experimental animals, liver tissues were extracted after experiment, and then fixed in a 4% paraformaldehyde solution after water removal. The fixed tissues were washed with running water, followed by dehydration in ethanol in sequential order of increased concentration. Then, the treated tissues were subjected to infiltration and embedding in paraffin, followed by preparing 4 μm tissue sections, staining the same with hematoxylin and eosin. Thereafter, the stained tissues were observed under an optical microscope.
- As compared to the normal diet group, the size of adipose cells in the high fat diet group was considerably increased, whereas the high fat diet and MSM-containing composition intake group showed significantly reduced size of adipose cells. Therefore, it could be confirmed that the composition of the present invention is useful for treatment and prevention of obesity caused by high fat diet.
-
FIG. 3 is micrographs showing liver tissue morphology in a high fat diet obese mouse model by the MSM-containing composition. It was observed inFIG. 3 that fat was accumulated throughout the high fat diet group compared to the normal diet group, while fat accumulation in the high fat diet and MSM-containing composition intake group was significantly reduced to be closer to the normal diet group. Accordingly, it could be assessed that the MSM-containing composition has efficacy in improving fatty liver. -
FIG. 4 is micrographs showing liver tissue morphology in a high fat diet obese mouse model by the MSM-containing composition. It was observed inFIG. 4 that fat was accumulated throughout the high fat diet group compared to the normal diet group, while fat accumulation in the high fat diet and MSM-containing composition intake group was significantly reduced to be closer to the normal diet group. Accordingly, it could be assessed that the MSM-containing composition has efficacy in improving fatty liver. - (1) 3T3-L1 Cell Culture and Differentiation
- Mouse-derived 3T3-L1 cells were obtained from the American Type Culture Collection (ATCC, CL-173, Manassas, Va., USA) and used. After seeding 3T3-L1 pre-adipocytes at 1×106 cells/well in 1000, 24-well and 96-well plates, respectively, depending upon purposes of the experiment, the cells were incubated in a high concentration of glucose DMEM (89%) containing BS(10%) and P/S(1%) to reach 100% confluence. 2 days later, the pre-adipocytes were subjected to induction of differentiation using an adipocyte differentiation-inducing substance (1 μg/mL insulin, 1 μM DEX, 0.5 mM IBMX) as well as DMEM containing FBS (10%) and P/S (10%). During adipocyte differentiation (day 0), samples were treated with DMEM at 25, 50 and 100 μg/mL, while a positive control was treated with 5 mM of NAC as an antioxidant, and then used for comparison.
- In order to determine 3T3-L1 cell differentiation inhibitory efficacy, an amount of triglycerides generated in 3T3-L1 adipocytes was measured by
Oil Red 0 staining to stain only triglycerides in red. A result of the measurement is shown inFIG. 5 . -
FIG. 5 is micrographs showing 3T3-L1 cell differentiation inhibitory effects in a high fat diet obese mouse model by the MSM-containing composition. As shown inFIG. 5 , it could be confirmed that 3T3-L1 cells were not differentiated owing to administration of the MSM-containing composition according to the present invention. - Breeding, diet and statistical treatment of the experimental animals were performed in the same manner as in Experimental Example 1. In order to confirm effects of improving blood lipids by the MSM-containing composition of the present invention, all animals were subjected to fasting for at least 12 hours after the end of experiment, followed by sacrificing and collecting blood. The collected blood was left at room temperature for 1 hour and then centrifuged at 3000 rpm to obtain serum, which in turn was analyzed using an automatic biochemical analyzer (BS-380, Mindray) to assess intrahepatic triglycerides and total cholesterol.
-
FIG. 6 is graphs illustrating measured results of change in liver triglyceride content in obese mice by the MSM-containing composition. -
FIG. 7 is graphs illustrating measured results of change in total liver cholesterol content in obese mice by the MSM-containing composition. - As shown in the figures, it could be confirmed that the triglyceride and total cholesterol contents have returned to substantially normal levels as a result of administration of the MSM-containing composition for 3 weeks to the obese mice.
- Lipolysis experiments were implemented using normal milk coffee and Korean chicken soup (“Samgyetang”). The milk coffee was added to the MSM-containing composition of the present invention and then dissolved, followed by visual observation of lipolysis.
-
FIG. 8 illustrates a result of in vitro lipolysis experiment using milk coffee with the MSM-containing composition. -
FIG. 9 illustrates a result of in vitro lipolysis experiment using Korean chicken soup (“Samgyetang”) with the MSM-containing composition. - As shown in the figures, it could be visually confirmed that fats were decomposed in the milk coffee and samgyetang to which the MSM-containing composition according to present invention was added, respectively.
- In the present experimental example, insulin-like growth factor (IGF-1) secretion ability of the MSM-containing composition was tested.
- Analyzers used herein were ELISA readers (LAB SYSTEM, USA) and ELISA kits (rat IGF-1, catalog #DSL 10-2900, Diagnostic Systems Laboratories, USA), while a data analysis and statistical system used herein was Prism (ver. 2.01, GraphPad Software Inc., USA).
- Sprague Dawley rats were used as test animals. The test animals were 3 weeks of age for the long-term administration test and 9 weeks of age for the IGF-1 evaluation test. The test animals were male and 30 animals were assigned for each test (10 for controls, 10 for examples, 10 for comparative examples). Breeding conditions of the test animals were set to: temperature 22±3 (19 to 25) ° C.; humidity 30 to 70%; photoperiod 12 hours (light cycle: 08:00 to 20:00).
- For IGF-1 evaluation test, all animals were used after fasting for 24 hours in order to control a basic amount of growth hormone in the blood or for concurrency. For the test group, a daily dose (1,500 mg/day based on a 60 kg human) was orally administered. The control group was supplied with the same volume of drinking water as the test group. Tail blood was collected at 0 hours and, after oral administration, 0.1 ml or less of blood was collected at 2 hour intervals up to 10 hours, followed by serum separation to prepare a measurement sample. IGF-I measurement was implemented using a kit product by means of ELISA.
- Since growth hormone secretion mostly occurs by instantaneous release called pulse mode, it is very difficult to measure a change in growth hormone secretion in response to physiological stimulation. Indeed, although the hormone flows through the bloodstream for only a few minutes, this is enough for the hormone to enter the liver and stimulate the same so as to be converted into growth factors in the liver. IGF-1 secretion is used to measure an amount of growth hormone secretion, wherein IGF-1 has more diverse activities than the growth hormone itself and directly acts on most biological activities. Therefore, in the present test, an amount of blood IGF-1 secretion as a secondary signal of growth hormone was measured, and IGF-1 remained stable in blood after stimulation and substantially showed effects of growth hormone.
-
FIG. 10 is graphs showing IGF-1 secretion ability of the MSM-containing composition. - As shown in the figure, the amount of IGF-1 secretion in the control group was continuously decreased, whereas the MSM-containing composition significantly increased the amount of IGF-1 secretion. Therefore, it could be confirmed that the MSM-containing composition according to the present invention exhibits excellent effects of promoting secretion of IGF-1, which is an insulin-like growth factor
Claims (6)
1. A pharmaceutical composition for preventing or treating obesity, comprising:
75 to 85% by weight (“wt. %”) of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
2. A pharmaceutical composition for preventing or treating fatty liver, comprising:
75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
3. A pharmaceutical composition for preventing or treating diabetes, comprising:
75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
4. A food composition for preventing or alleviating obesity, comprising:
75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
5. A food composition for preventing or improving fatty liver, comprising:
75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
6. A food composition for preventing or alleviating diabetes, comprising:
75 to 85 wt. % of methylsulfonylmethane (MSM: dimethyl sulfone); 0.5 to 2 wt. % of vitamin B6 hydrochloride; 0.01 to 1 wt. % of folic acid; 2 to 8 wt. % of galactooligosaccharide; 10 to 18 wt. % of rice fermented magnesium; and 0.5 to 3 wt. % of vitamin C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0095802 | 2018-08-17 | ||
KR1020180095802A KR101957502B1 (en) | 2018-08-17 | 2018-08-17 | Composition for preventing or improving obsity, fatty liver and diabetes comprising Methyl Sulfonyl Methane: Dimethyl Sulfone |
PCT/KR2018/012675 WO2020036257A1 (en) | 2018-08-17 | 2018-10-25 | Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210267912A1 true US20210267912A1 (en) | 2021-09-02 |
Family
ID=65800156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/252,676 Abandoned US20210267912A1 (en) | 2018-08-17 | 2018-10-25 | Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210267912A1 (en) |
JP (1) | JP2021535121A (en) |
KR (1) | KR101957502B1 (en) |
CN (1) | CN112584825A (en) |
WO (1) | WO2020036257A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011527194A (en) * | 2008-07-07 | 2011-10-27 | ザ・アイムス・カンパニー | Probiotic dietary supplements and methods for their production and packaging |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
MXPA02011939A (en) * | 2000-06-02 | 2003-04-22 | Procter & Gamble | Low carbohydrate compositions, kits thereof, and methods of use. |
CN1425386A (en) * | 2002-12-25 | 2003-06-25 | 大连鑫碟甲壳素有限公司 | Dimethyl-sulfone sulfide supplementary agent and its overlapped health articles |
WO2005107728A2 (en) * | 2004-05-06 | 2005-11-17 | Hofmann Robert F | Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
JPWO2005112667A1 (en) * | 2004-05-20 | 2008-03-27 | 隆史 大森 | healthy food |
JP2008525320A (en) * | 2004-12-24 | 2008-07-17 | ドルフィスト・プロプライエタリー・リミテッド | Formulation and treatment for welfare |
CN101262887A (en) * | 2005-07-15 | 2008-09-10 | 视可舒研究公司 | Prevention and treatment of ophthalmic complications of diabetes |
KR20070113460A (en) * | 2006-05-24 | 2007-11-29 | 주식회사 산테 | The health food composition for regulating weight |
WO2011048617A2 (en) * | 2009-10-19 | 2011-04-28 | Laila Nutraceuticals | Extracts, fractions and compositions comprising acetogenins and their applications |
KR101171832B1 (en) * | 2009-10-30 | 2012-08-14 | 박경식 | Tea compositions for long term dose of without side effects, its' components |
KR101465554B1 (en) * | 2013-03-25 | 2014-11-26 | 이승훈 | A functional food composition for triglyceride in blood and reducing inflammation level containing Methyl Sulfonyl Methane |
KR20140116988A (en) * | 2013-03-25 | 2014-10-07 | 이승훈 | A pharmaceutical composition for preventing and treating rheumarthritis and lipid metabolism related disease containing Methyl Sulfonyl Methane |
-
2018
- 2018-08-17 KR KR1020180095802A patent/KR101957502B1/en active IP Right Grant
- 2018-10-25 WO PCT/KR2018/012675 patent/WO2020036257A1/en active Application Filing
- 2018-10-25 CN CN201880096705.4A patent/CN112584825A/en active Pending
- 2018-10-25 JP JP2021510080A patent/JP2021535121A/en active Pending
- 2018-10-25 US US17/252,676 patent/US20210267912A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011527194A (en) * | 2008-07-07 | 2011-10-27 | ザ・アイムス・カンパニー | Probiotic dietary supplements and methods for their production and packaging |
Non-Patent Citations (2)
Title |
---|
JP 2011/527194 A- "Probiotic Dietary Supplements And Methods For Their Production And Packaging", Published on 10/27/2011; English translation, total pages 1-26. (Year: 2011) * |
LEE S.H., "A Functional Food Composition For Triglyceride In Blood And Reducing Inflammation Level Containing Methyl Sulfonyl Methane", KR 2014/0116606 A1; Published on 10/06/2014; English translation, total pages 1-9. (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
WO2020036257A1 (en) | 2020-02-20 |
KR101957502B1 (en) | 2019-03-12 |
CN112584825A (en) | 2021-03-30 |
JP2021535121A (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102292093B (en) | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome | |
JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
AU2017337936A1 (en) | Novel Lactobacillus Sakei And Composition Comprising The Same | |
WO2015072674A1 (en) | Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases | |
CN105555286A (en) | Activated soy pod fiber | |
JP2021501119A (en) | Visceral fat obesity prevention, amelioration or therapeutic composition containing Danshen extract | |
KR20190090362A (en) | A composition for imobesity containing dicaffeoylquinic acid | |
KR101213825B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient | |
KR20210082974A (en) | Composition for preventing or treating metabolic disease comprising Nymphoides peltata extract | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
KR101931226B1 (en) | Composition for preventing, alleviating or treating disorder associated with polycystic ovary syndrome comprising extract of Cassiae Semen as effective component | |
CN110327399A (en) | Beautyberry extract is preparing the application in fat-reducing medicament | |
KR20130081929A (en) | Composition comprising dieckol compound for treating insulin resistance or hyperinsulinemia | |
KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
US20210267912A1 (en) | Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes | |
KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
KR101660834B1 (en) | Anti-diabetic effects of Gypenoside 75 | |
KR102160424B1 (en) | Composition for preventing, treating or improving obesity comprising Eupatilin as an active ingredient | |
US20090318552A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof | |
KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
KR101881144B1 (en) | Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising Dryopteris crassirhizpma extract as effective component | |
KR101688126B1 (en) | A pharmaceutical composition for preventing or treating obesity or hyperlipidemia, and method of preparing the same | |
KR100535322B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum Rottler for treating or preventing diabetes mellitus | |
KR102534210B1 (en) | Pharmaceutical Composition comprising Nidus vespae extract as an active ingredient for Preventing or Treating obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |